**EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN**

<table>
<thead>
<tr>
<th>Form Name/activity</th>
<th>Number of pharmacies</th>
<th>Total burden hours</th>
<th>Average hourly wage rate *</th>
<th>Total cost burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cognitive interviews</td>
<td>20</td>
<td>30</td>
<td>$32.28</td>
<td>$968</td>
</tr>
<tr>
<td>Pretest</td>
<td>60</td>
<td>157</td>
<td>$22.08</td>
<td>$3,467</td>
</tr>
<tr>
<td>Pharmacy background questionnaire</td>
<td>60</td>
<td>10</td>
<td>$51.27</td>
<td>$513</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>140</strong></td>
<td><strong>197</strong></td>
<td>na</td>
<td><strong>$4,948</strong></td>
</tr>
</tbody>
</table>

*Based upon the mean of the average hourly wages for Pharmacists (29–1051; $51.27), Pharmacy Technicians (29–2052; $13.92), and Pharmacy Aides (31–9095; $10.74), National Compensation Survey: Occupational wages in the United States May 2009, “U.S. Department of Labor, Bureau of Labor Statistics.” The hourly wage for the cognitive interviews is a weighted average for 10 pharmacists, 8 pharmacy technicians and 2 pharmacy aides; the hourly wage for the pretest is a weighted average for 157 pharmacists, 235 pharmacy technicians and 235 pharmacy aides.

**Estimated Annual Costs to the Federal Government**

Exhibit 3 shows the estimated total and annualized cost for this project.

Although data collection will last for less than one year, the entire project will take about 3 years. The total cost for this project is approximately $320,818.

**EXHIBIT 3—ESTIMATED TOTAL AND ANNUALIZED COST**

<table>
<thead>
<tr>
<th>Cost component</th>
<th>Total cost</th>
<th>Annualized cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Development</td>
<td>$65,340</td>
<td>$21,780</td>
</tr>
<tr>
<td>Data Collection Activities</td>
<td>62,831</td>
<td>20,944</td>
</tr>
<tr>
<td>Data Processing and Analysis</td>
<td>11,004</td>
<td>3,368</td>
</tr>
<tr>
<td>Publication of Results</td>
<td>15,767</td>
<td>5,256</td>
</tr>
<tr>
<td>Project Management</td>
<td>7,496</td>
<td>2,498</td>
</tr>
<tr>
<td>Overhead</td>
<td>158,380</td>
<td>5,293</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>320,818</strong></td>
<td><strong>106,939</strong></td>
</tr>
</tbody>
</table>

**Request for Comments**

In accordance with the Paperwork Reduction Act, comments on AHRQ’s information collection are requested with regard to any of the following: (a) Whether the proposed collection of information is necessary for the proper performance of AHRQ healthcare research and healthcare information dissemination functions, including whether the information will have practical utility; (b) the accuracy of AHRQ’s estimate of burden (including hours and costs) of the proposed collection(s) of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the Agency’s subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record.

Dated: May 10, 2011.

Carolyn M. Clancy,  
Director.

[FR Doc. 2011–12505 Filed 5–23–11; 8:45 am]

BILLING CODE 4160–90–M

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Interagency Committee on Smoking and Health: Notice of Charter Renewal**

This gives notice under the Federal Advisory Committee Act (Pub. L. 92–463) of October 6, 1972, that the Interagency Committee on Smoking and Health, Department of Health and Human Services, has been renewed for a 2-year period through March 20, 2013.

For information, contact Dana Shelton, Designated Federal Officer, Interagency Committee on Smoking and Health, Centers for Disease Control and Prevention, Department of Health and Human Services, 1600 Clifton Road, M/S K–50, Atlanta, Georgia 30333, telephone 770/488–5709 or fax 770/488–5767.

Dated: April 11, 2011.

Elaine L. Baker,  
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011–12568 Filed 5–23–11; 8:45 am]

BILLING CODE 4163–18–P

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated...
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 76, FR 24886–24887, dated May 3, 2011) is amended to reflect the reorganization of the National Center for Injury Prevention and Control, Office of Noncommunicable Diseases, Injury and Environmental Health, Centers for Disease Control and Prevention.

Section C–B, Organization and Functions, is hereby amended as follows:

Delete in their entirety the title and functional statement for the Office of the Director, (CUHC1) and insert the following: Office of the Director, (CUHC1). (1) Establishes and interprets policies and determines program priorities; (2) provides national and international leadership and guidance in policy formation and program planning, development, and evaluation; (3) provides administrative, fiscal, and technical support for division programs and units; (4) assures multi-disciplinary collaboration in violence prevention and control activities; (5) provides leadership for developing research in etiologic, epidemiologic, and behavioral aspects of violence prevention and control; (6) coordinates domestic and international activities within the division and with others involved in violence prevention; (7) prepares and monitors clearance of manuscripts for publication in scientific and technical journals and publications, including articles and guidelines published in the MMWR, and other publications for the public; (8) prepares, tracks and distributes print, broadcast, and electronic materials for use in programs at the national and state levels; (11) provides technical assistance and consultation to domestic and international governmental and non-governmental organizations on violence prevention; and (12) establishes linkages and collaborates, as appropriate, with other divisions and offices in NCIPC, other CIOs throughout CDC, and with national and international prevention partners that impact on violence prevention programs.

Departments and agencies include:

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Draft Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance entitled “Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators.” This draft guidance is intended to assist clinical investigators, industry, and FDA staff in interpreting and complying with the regulations governing financial disclosure by clinical investigators. This guidance provides FDA’s responses to the most frequently asked questions regarding financial disclosure by clinical investigators.

DATES: Although comments on any guidance can be submitted at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers a comment on this draft guidance before we work on the final version of the guidance, electronic or written comments on the draft guidance should be submitted by July 25, 2011. Submit written comments on the draft guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Marsha Melvin, Office of Good Clinical Practice, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 29, rm. 6033, Silver Spring, MD 20993–0002, 301–796–8345.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft guidance entitled “Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators.” This guidance is intended to assist clinical investigators, industry, and FDA staff in interpreting and complying with the regulations governing financial disclosure by clinical investigators. When finalized, this guidance will supersede “Guidance for Industry—Financial Disclosure by Clinical Investigators” (March 20, 2001, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health).

This guidance also responds to recommendations made by the Office of the Inspector General (OIG), Department of Health and Human Services, in their report entitled “The Food and Drug Administration’s Oversight of Clinical Investigators’ Financial Information.” The OIG’s recommendations were intended to strengthen FDA’s oversight.